Versuchen GOLD - Frei
"To achieve our 'Skilled India' vision, we'll train a large number of individuals quickly and to high standards"
Bio Spectrum
|BioSpectrum India Nov 2024
Jayant Singh Chaudhary, Union Minister of State (Independent Charge), Skill Development and Entrepreneurship, Government of India, in an interaction with BioSpecturm in Hyderabad, shares his insights on the various initiatives taken up by the Centre for skill development programmes, boosting self-employment. He exudes confidence that the new BioE3 Policy will give a new direction to the Indian industry, further grounding its roots and boosting its manufacturing prowess to meet the domestic needs and global demands in key areas of pharma, biotechnology and other sectors.

What according to you are the key objectives of the BioE3 policy and how is it going to boost the industrial sector in the country?
The BioE3 (Biotechnology for Economy, Environment, and Employment) Policy aims to position India as a leader in bio-manufacturing and address critical challenges like climate change and resource sustainability. Its main objectives include increasing Research and Innovation, Strengthening Domestic Bio-manufacturing, Promoting AI and Digital Tools, Establishing Facilities and most importantly developing a skilled workforce.
I am quite confident that by increasing research and innovation, the industry can focus on solutions to tackle climate change and reduce carbon emissions. Enhancing collaborations among science, technology, engineering and manufacturing sectors will strengthen domestic Bio-manufacturing. I believe this new BioE3 policy is going to put more stress on encouraging the use of advanced technologies alongside biotechnology innovations and this will promote India in Artificial Intelligence and Digital Tools. This policy will also enable the creation of Bio-manufacturing Hubs and Biofoundries to support scalable production. Above all nurturing a skilled workforce is very important. This policy stresses developing a talented workforce which is needed to drive innovation and boost the next level of the Industrial Revolution in the country.
What specific initiatives is the government implementing to foster a skill development ecosystem for startups involved in Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs), and bio-pharma sectors, especially in terms of adhering to sustainable environmental norms?
The government is committed to fostering a robust skill development ecosystem for startups in APIs, KSMs, and bio-pharma sectors. To achieve this goal, we are implementing several specific initiatives.
Diese Geschichte stammt aus der BioSpectrum India Nov 2024-Ausgabe von Bio Spectrum.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON Bio Spectrum

Bio Spectrum
India's Pharma Reforms Target Global Credibility
The Indian government has introduced several measures to simplify drug approvals and support innovation.
9 mins
October 2025

Bio Spectrum
How Waste Management Strategies Can Transform Indian Pharma Manufacturing
Sustainability will be a key success factor as India's pharmaceutical industry enters its next stage of expansion.
7 mins
October 2025

Bio Spectrum
IASST synthesises new compound to combat aggressive breast cancer
A newly designed nitro-substituted organoselenium compound by Guwahati-based Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science and Technology (DST), can reduce the invasiveness of aggressive triplenegative breast cancer cells by modulating various Se Se signalling pathways.
1 min
October 2025
Bio Spectrum
DPIIT signs MoU with Pfizer to strengthen healthcare innovation ecosystem
In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Pfizer Limited.
1 min
October 2025

Bio Spectrum
WHO unveils updated guideline on HIV service delivery
WHO has released an updated guideline to support integrated HIV service delivery, promote long-term adherence to antiretroviral therapy (ART), and improve the overall health and well-being of people living with HIV.
1 min
October 2025
Bio Spectrum
Scientists in Kolkata explore therapeutic potential of accessory proteins
A hidden protein that protects our cells from mechanical stress could provide a new direction to therapeutic strategies for diseases where protein stability under force is compromised like heart muscle disease or genetic disorders called laminopathies.
1 min
October 2025

Bio Spectrum
US FDA advances rare disease drug development
The US Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.
1 min
October 2025
Bio Spectrum
WHO updates list of essential medicines to include key cancer, diabetes treatments
The World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLC), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.
1 min
October 2025
Bio Spectrum
Agilent's MMR IHC Panel pharmDx (Dako Omnis) receives European IVDR Certification
Agilent Technologies Inc. has announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer.
1 min
October 2025
Bio Spectrum
Aodh Lifesciences gets support from TDB to redefine pneumonia treatment
The Technology Development Board (TDB), Department of Science and Technology, Government of India, has extended support to Aodh Lifesciences, a startup based in Hyderabad, for development of Indigenous Antibiotic Nebulisation Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).
1 min
October 2025
Listen
Translate
Change font size